Healthcare advertising company Talking Medicines is launching Drug-GPT, an artificial intelligence-powered tool that analyzes social data for healthcare marketing companies.
The tool is now available on the company's PatientMetRx platform. The company licensed the GPT models from Microsoft, according to a May 11 Talking Medicines news release.
"We are really excited by the potential of Drug-GPT to transform the way that healthcare advertising agencies analyze insights on complex patient and healthcare professionals' social data," Talking Medicines co-founder and CEO Jo Halliday said in the release. "With structured and actionable insights delivered within seconds, it provides our customers with the edge to win business, create amazing content, and deliver successful campaigns. With Drug-GPT and PatientMetRx 2.0, we truly believe we can unlock the power of AI to transform healthcare marketing."